NEW YORK, Jan. 17, 2017 /PRNewswire/ -- Harwood
Feffer LLP (www.hfesq.com) is investigating potential claims
against the board of directors of Derma Sciences Inc. ("Derma" or
the "Company") (NASDAQ: DSCI) concerning the proposed acquisition
of the Company by Integra LifeSciences Holdings Corporation
("Integra").
Under the terms of the offer, Integra would acquire Derma in a
transaction valued at approximately $240
million. Pursuant to the terms of the transaction,
Derma shareholders would receive $7.00 in cash per share owned. One Wall
Street analyst set a price target for Derma shares of $8.50 per share.
Our investigation concerns whether the Derma board of directors
is fulfilling its fiduciary duties, maximizing the value of the
Company, disclosing all material benefits and costs, and obtaining
full and fair consideration for Company stockholders.
If you own Derma shares and wish to discuss this matter with us,
or have any questions concerning your rights and interests with
regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-derma-sciences-inc-300392364.html
SOURCE Harwood Feffer LLP
